{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-026840","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2022-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.394748+00:00","generated_at":"2026-06-23T07:35:26.592424+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Lineage Cell Therapeutics amends employment agreements and adopts bonus plan","bullets":["New employment agreements set salaries: CEO $690k, GC $394.8k, SVP $366.8k; bonus targets 55%, 40%, 35% respectively.","Termination benefits enhanced: CEO receives 12 months salary + 100% bonus (18 months + 150% on change of control); others receive 9 months + pro-rata (12 months + 100% on change of control).","New Executive Performance Incentive Bonus Plan adopted; bonuses tied to financial, clinical, and operational goals determined by Compensation Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-026840","json":"https://secwatch.observer/filing/0001493152-22-026840.json","markdown":"https://secwatch.observer/filing/0001493152-22-026840.md","text":"https://secwatch.observer/filing/0001493152-22-026840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315222026840/0001493152-22-026840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315222026840/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:35:26.592424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}